215 related articles for article (PubMed ID: 19091547)
1. Validation of novel imaging methodologies for use as cancer clinical trial end-points.
Sargent DJ; Rubinstein L; Schwartz L; Dancey JE; Gatsonis C; Dodd LE; Shankar LK
Eur J Cancer; 2009 Jan; 45(2):290-9. PubMed ID: 19091547
[TBL] [Abstract][Full Text] [Related]
2. The power of phase II end-points for different possible mechanisms of action of an experimental treatment.
Wason JM; Dentamaro A; Eisen TG
Eur J Cancer; 2015 May; 51(8):984-92. PubMed ID: 25840669
[TBL] [Abstract][Full Text] [Related]
3. Alternative clinical end points in rectal cancer--are we getting closer?
Glynne-Jones R; Mawdsley S; Pearce T; Buyse M
Ann Oncol; 2006 Aug; 17(8):1239-48. PubMed ID: 16873440
[TBL] [Abstract][Full Text] [Related]
4. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
[TBL] [Abstract][Full Text] [Related]
6. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
7. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
[TBL] [Abstract][Full Text] [Related]
8. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.
Schwartz LH; Seymour L; Litière S; Ford R; Gwyther S; Mandrekar S; Shankar L; Bogaerts J; Chen A; Dancey J; Hayes W; Hodi FS; Hoekstra OS; Huang EP; Lin N; Liu Y; Therasse P; Wolchok JD; de Vries E
Eur J Cancer; 2016 Jul; 62():138-45. PubMed ID: 27237360
[TBL] [Abstract][Full Text] [Related]
9. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA; Therasse P; Bogaerts J; Schwartz LH; Sargent D; Ford R; Dancey J; Arbuck S; Gwyther S; Mooney M; Rubinstein L; Shankar L; Dodd L; Kaplan R; Lacombe D; Verweij J
Eur J Cancer; 2009 Jan; 45(2):228-47. PubMed ID: 19097774
[TBL] [Abstract][Full Text] [Related]
10. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
Tolaney SM; Garrett-Mayer E; White J; Blinder VS; Foster JC; Amiri-Kordestani L; Hwang ES; Bliss JM; Rakovitch E; Perlmutter J; Spears PA; Frank E; Tung NM; Elias AD; Cameron D; Denduluri N; Best AF; DiLeo A; Baizer L; Butler LP; Schwartz E; Winer EP; Korde LA
J Clin Oncol; 2021 Aug; 39(24):2720-2731. PubMed ID: 34003702
[TBL] [Abstract][Full Text] [Related]
11. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
[TBL] [Abstract][Full Text] [Related]
12. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
13. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
15. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
16. Optimising the design of phase II oncology trials: the importance of randomisation.
Ratain MJ; Sargent DJ
Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review.
Rahib L; Fleshman JM; Matrisian LM; Berlin JD
JAMA Oncol; 2016 Sep; 2(9):1209-16. PubMed ID: 27270617
[TBL] [Abstract][Full Text] [Related]
18. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma.
Brandes AA; Franceschi E; Gorlia T; Wick W; Jacobs AH; Baumert BG; van den Bent M; Weller M; Stupp R;
Eur J Cancer; 2012 Apr; 48(6):896-903. PubMed ID: 22119352
[TBL] [Abstract][Full Text] [Related]
19. Considerations for the use of imaging tools for phase II treatment trials in oncology.
Shankar LK; Van den Abbeele A; Yap J; Benjamin R; Scheutze S; Fitzgerald TJ
Clin Cancer Res; 2009 Mar; 15(6):1891-7. PubMed ID: 19276276
[TBL] [Abstract][Full Text] [Related]
20. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.
Borow KM; Yaroshinsky A; Greenberg B; Perin EC
Circ Res; 2019 Jul; 125(3):265-281. PubMed ID: 31318648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
